Basic Lanoxin Information

• INN (International Nonproprietary Name): Digoxin
• Brand Names Available In United Kingdom: Lanoxin, Digoxin tablets; oral elixir also available
• ATC Code: C01AA05
• Forms & Dosages: Tablets 0.0625 mg, 0.125 mg, 0.25 mg; Oral solution/elixir 0.05 mg/mL; Injection (ampoules) 0.25 mg/mL (2 mL)
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: Licensed by MHRA (Lanoxin and generics)
• OTC / Rx Classification: Prescription‑only (POM) across major markets and the UK

Critical Warnings & Restrictions

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Is this drug safe for everyone? No — digoxin has a narrow therapeutic index and requires careful dosing and monitoring.

Absolute contraindications include ventricular fibrillation, known hypersensitivity to digitalis, acute myocarditis and severe AV block unless paced.

Older people are at higher risk owing to reduced renal clearance and increased sensitivity to cardiac and neurological effects.

Patients with renal impairment require substantial dose reduction and frequent checks of serum digoxin and renal function.

Electrolyte disturbances such as hypokalaemia or hypomagnesaemia, and hypercalcaemia, markedly increase the risk of digoxin toxicity.

Children need weight‑based dosing and special paediatric preparations because neonates and infants are more sensitive.

Pregnancy and breastfeeding require specialist assessment; use only if benefits outweigh risks and arrange multidisciplinary obstetric and neonatal monitoring.

• High‑risk markers: age over 70, estimated glomerular filtration rate reduction, recent diuretic use causing low potassium, history of conduction disease, visual disturbance with treatment.
• Immediate action checklist: stop the drug and seek urgent care for severe vomiting, new fainting, marked visual changes, severe GI upset or palpitations that suggest arrhythmia.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Can digoxin affect your ability to drive or operate machines? Yes — it can cause dizziness, visual disturbance, confusion and arrhythmias that impair safe driving.

Patients must not drive if these symptoms occur and should be advised to stop driving until symptoms resolve and a clinician confirms fitness to drive.

Clinicians and pharmacists should document counselling about driving and workplace safety in the patient record.

Q&A — “Can I Drive After Taking It In The UK?”

Short answer: Only if you remain symptom‑free.

If you experience dizziness, fainting, significant visual change or confusion, do not drive and inform your GP or specialist and the DVLA if required.

Report side effects to the MHRA Yellow Card scheme.

Usage Basics

INN, Brand Names Available In The UK

The International Nonproprietary Name (INN) is digoxin.

Common brand names in the United Kingdom include Lanoxin and generic digoxin tablets, with oral elixir available for paediatric use.

Legal Classification (POM, P, GSL)

Digoxin is a prescription‑only medicine (POM) in the UK and cannot be supplied over the counter.

Injectable forms are generally restricted to hospital or clinical settings.

Prescriptions can be submitted electronically via the NHS Electronic Prescription Service (EPS) for pharmacy collection.

• Who prescribes: hospital cardiologists, GPs continuing treatment after specialist advice, paediatric cardiology teams for children.
• Where to obtain: community pharmacies, hospital pharmacies, and MHRA‑registered online pharmacies on receipt of a valid prescription.

Dosing Guide

Standard Regimens (NHS Guidelines)

Typical adult maintenance dosing is 0.125–0.25 mg once daily and must be individualised to clinical response and serum digoxin levels.

Many older patients start at the lower end of the range to reduce the risk of toxicity.

Paediatric dosing is weight‑based; typical oral maintenance is about 5–10 mcg/kg/day with loading and IV therapy reserved for specialist inpatient care.

Adjustments For Comorbidities

Renal impairment requires substantial dose reduction because digoxin is primarily renally cleared.

Elderly patients often need a lower maintenance dose and closer monitoring.

Hepatic impairment does not usually require dose reduction if renal function is normal, but clinical monitoring remains important.

Q&A — “What If I Miss A Dose?”

Take the missed tablet as soon as you remember unless the next dose is due soon, in which case skip the missed dose.

Do not double up to make up for a missed dose.

If you have severe vomiting or diarrhoea, contact your prescriber because absorption and serum levels can change.

Initiation Checklist: baseline ECG, renal function, electrolytes, review of concomitant medicines, agreed monitoring schedule.

Interaction Chart

Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)

There is no specific food prohibition, but dehydration and GI losses increase toxicity risk by altering renal clearance and electrolytes.

Very high‑fibre meals may reduce digoxin absorption in some patients; advise a consistent diet.

Alcohol can worsen arrhythmias or interact with comorbidities, so counsel moderation in drinkers.

Common Drug Conflicts (MHRA Yellow Card Data)

Many medicines alter digoxin plasma concentrations or predispose to toxicity and require monitoring or dose adjustment.

After adding an interacting agent, arrange serum digoxin and electrolyte checks and report suspected adverse reactions via the MHRA Yellow Card scheme.

User Reports & Trends

What do patients say online and in clinic? Many describe tangible symptom relief but also concerns about monitoring and toxicity.

• Benefits reported: improved breathlessness and symptom control for some patients with heart failure and better ventricular rate control in atrial fibrillation.
• Burdens reported: the need for regular blood tests, fear of toxicity, visual disturbances and gastrointestinal upset.
• Common forum themes: reliance on pharmacist counselling, queries about dose adjustments and worries about interactions with diuretics.

Clinicians should validate these experiences, arrange clear monitoring plans and signpost reliable NHS resources such as Patient.info for balanced information.

Access & Purchase Options

Boots, LloydsPharmacy, Superdrug (And Pharmacy Chains)

Lanoxin and generic digoxin are supplied via prescription through major UK chains and independent community pharmacies.

Hospital discharge prescriptions often direct patients to a nominated community pharmacy.

Online Pharmacies And NHS E‑Prescriptions

The NHS Electronic Prescription Service (EPS) allows prescriptions to be sent to a nominated community or online pharmacy for collection or delivery.

MHRA‑registered online pharmacies will dispense digoxin on receipt of a valid prescription; always verify GPhC accreditation when ordering online.

In our online pharmacy, lanoxin is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

• Bring an up‑to‑date medicines list to every dispensing encounter.
• Verify dose, strength, batch and expiry and confirm monitoring arrangements with the pharmacist.
• Never buy digoxin from unauthorised sellers; this increases poisoning risk.

Mechanism & Pharmacology

Simplified Explanation

Digoxin is a cardiac glycoside that inhibits the myocardial Na+/K+‑ATPase pump.

Inhibition raises intracellular sodium and, via the sodium‑calcium exchanger, increases intracellular calcium to improve contractility.

Digoxin also increases vagal tone and slows conduction through the atrioventricular node, which helps rate control in atrial fibrillation.

Clinical Terms

• Na+/K+‑ATPase: the membrane pump digoxin inhibits to change intracellular ion balance.
• Positive inotrope: increases the strength of cardiac contraction.
• AV Nodal Conduction: slowing this reduces ventricular rate in atrial fibrillation.
• Therapeutic Index: digoxin has a narrow window between effective and toxic concentrations, so monitoring is required.

Pharmacokinetic points: oral bioavailability is variable, elimination is primarily renal and half‑life is prolonged in renal impairment.

Small changes in dose, renal function or interacting drugs can produce toxicity, so monitoring is essential.

Indications & Off‑Label Uses

MHRA‑Approved Uses

Off‑Label Practices In NHS And Private Care

Specialist teams sometimes use digoxin off‑label for selected paediatric arrhythmias or as an adjunct where beta‑blockers or calcium channel blockers are unsuitable.

Off‑label prescribing should be documented with informed consent and clear specialist oversight.

Alternatives such as digitoxin, amiodarone or beta‑blockers are considered when conduction disease, bradyarrhythmia or renal impairment complicate digoxin use.

Key Clinical Findings

What does contemporary evidence say? Digoxin offers symptomatic benefit in selected patients with heart failure and assists with rate control in atrial fibrillation, but overall mortality benefit is neutral.

Guidelines recommend individualised use, regular serum monitoring and consideration of alternatives for patients at higher risk of toxicity.

Observational studies link higher digoxin concentrations with worse outcomes, supporting target‑guided dosing and lower maintenance levels where effective.

Clinicians should reference NICE and MHRA guidance and local formularies when starting therapy.

Start‑therapy checklist: confirm indication, document alternatives tried, ensure monitoring capacity and plan review dates.

Alternatives Matrix

NHS Prescribing Alternatives (Comparison Table)

Pros And Cons Checklist

• Bisoprolol and metoprolol are effective for both systolic heart failure and rate control but need dose titration and heart rate monitoring.
• Amiodarone is effective for rhythm control but has a significant monitoring burden and long‑term toxicities.
• Digitoxin may be considered if renal clearance of digoxin is problematic, but specialist advice is needed due to differing pharmacokinetics.

Choose alternatives when conduction disease, bradycardia or inability to monitor digoxin levels are present, or when interactions make digoxin unsafe.

Common Questions

Here are top FAQs asked by patients in UK clinics and pharmacies.

• Can I breastfeed on digoxin? Small amounts are excreted in breast milk; breastfeeding is often allowed but clinical review and monitoring of the infant are recommended if concerns exist.
• Will digoxin affect my eyesight? Visual changes such as blurred or yellow vision, or seeing halos, can signal toxicity and require urgent review.
• How often will I need blood tests? Baseline creatinine, electrolytes and ECG before starting; repeat digoxin level and electrolytes at steady state or after dose changes and then at clinician‑determined intervals.
• Can I stop it if I feel better? Do not stop digoxin without consulting your prescriber as abrupt cessation may worsen symptoms or control.

For patient leaflets, use collapsible Q&A formats and signpost NHS patient.info and the MHRA Yellow Card scheme for reporting side effects.

NHS Cost & Access Comparison Table

Checklist for claiming exemptions: age, pregnancy, income‑based benefits and other categories — check the NHS website for current rules.

Registration & Regulation

MHRA Approval Process

Lanoxin and digoxin generics are MHRA‑licensed in the UK and safety updates, licence changes and batch recalls are issued via the MHRA.

Clinicians and pharmacists should keep up to date with MHRA safety notices and report suspected adverse reactions via Yellow Card.

NHS Prescribing Framework

Local formularies and shared care agreements commonly govern initiation and monitoring of digoxin.

Community GPs often continue maintenance therapy after hospital initiation under agreed pathways and with documented monitoring schedules.

Pharmacists should verify a valid prescription, counsel patients on side effects and monitoring and escalate concerns to the prescriber.

Storage & Handling

UK Household Storage (Cold/Damp Climate)

Store tablets and ampoules at room temperature (20–25°C/68–77°F) and avoid humidity and extremes of heat.

In UK homes, avoid storing medicines in bathrooms or above kitchen sinks where dampness is likely.

Keep medicines in their original packaging and out of reach of children using child‑resistant containers where available.

Guidance From NHS And Pharmacists

Ampoules and injectables should be handled only in clinical settings; do not store opened vials at home for later use.

Return unused or expired medicines to a community pharmacy for safe disposal — do not flush them down the toilet.

When travelling, carry a copy of your prescription, keep tablets in the original packaging and store them away from heat and direct sunlight.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Key counselling points to record and communicate include the indication, exact strength and timing of the dose and what to do if vomiting or diarrhoea occurs.

Explain signs of toxicity such as GI upset, visual changes, confusion and palpitations and advise when to seek urgent care.

Confirm renal monitoring arrangements and advise on the MHRA Yellow Card for reporting side effects.

NHS Patient Safety Advice

Safety checklist for patients: baseline ECG, renal function and electrolytes before starting, arrange blood test at steady state and after dose or medication changes.

Keep an up‑to‑date medicines list and inform all clinicians about digoxin use.

Avoid OTC potassium‑altering remedies without advice and do not buy digoxin from unauthorised sellers.

Provide patients with a written plan that lists who to contact (GP, cardiology clinic, emergency services), the planned review date and the pharmacy contact.

Delivery Across United Kingdom

Final Practical Tools

Provide a short patient leaflet template that states the indication, dose, monitoring plan and red‑flag symptoms requiring urgent review.

Use a structured clinician checklist when prescribing: confirm indication, list alternatives, document monitoring schedule and arrange follow‑up lab tests at steady state.

Audit templates should capture indication, baseline tests, date of first level and outcome of level checks to support safe ongoing therapy.

When in doubt, consult cardiology colleagues and the local formulary to ensure the safest choice for each patient.